Clinical trial
AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus
NCT00241605 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00241605 |
|---|---|
| Title | AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus |
| Official title | AVANDAMET Compared to Metformin Evaluation Trial (ACME): A 48-week Randomized, Open-label, Multicenter Study to Compare the Efficacy and Tolerability of AVANDAMET to Metformin Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Control on Submaximal Metformin. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | rosiglitazone/metformin |
| Enrollment | 600 |
| Start date | Jun 25, 2003 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 16, 2005 |
| First posted | Oct 19, 2005 |
| Last update posted | Mar 21, 2018 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: